ROBBIN MULINA: Open Payments
NPI 1992154900 · HOUMA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,773 in 88 payments from 13 companies in 2025. Trend: 2023 $1,233 · 2024 $1,848 · 2025 $1,773
Food & beverage: $1,772Education: $1
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 10 | $327 |
| Otsuka America Pharmaceutical, Inc. | 16 | $292 |
| ABBVIE INC. | 15 | $234 |
| E.R. Squibb & Sons, L.L.C. | 13 | $186 |
| Vanda Pharmaceuticals Inc. | 8 | $174 |
| Janssen Pharmaceuticals, Inc | 7 | $146 |
| Neurocrine BioSciences, Inc. | 4 | $117 |
| Teva Pharmaceuticals USA, Inc. | 4 | $77 |
| Alkermes, Inc. | 3 | $73 |
| Lundbeck LLC | 4 | $69 |
Products named: Qelbree, VRAYLAR, REXULTI, COBENFY, FANAPT, ABILIFY ASIMTUFII, INGREZZA, INVEGA SUSTENNA.
Industry payments across LA — which companies pay providers there.
